Cargando…
Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
In this manuscript, we discuss the expectations versus the real-world results of four repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone from a clinical and pharmacovigilant point of view. We suggest that though the results of two-phase III double-blind clinical trial...
Autor principal: | Kelleni, Mina T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894610/ https://www.ncbi.nlm.nih.gov/pubmed/33644693 http://dx.doi.org/10.1007/s42399-021-00824-4 |
Ejemplares similares
-
Acute Psychosis in COVID-19: Is It Due to Favipiravir Treatment or Acute Viral Illness?
por: Duyan, Murat, et al.
Publicado: (2021) -
How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework
por: Sharma, Tanmay, et al.
Publicado: (2022) -
Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
por: Patel, Dimple, et al.
Publicado: (2023) -
Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective
por: Gandhi, Zainab, et al.
Publicado: (2020) -
Evaluation of the Treatment Efficacy and Safety of Remdesivir for COVID-19: a Meta-analysis
por: Tao, Jun, et al.
Publicado: (2021)